1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Remibrutinib REMIXes The Itch Record

 
• By Elizabeth Cairns

Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.  

Itching

Novartis AG and Roche Holding AG’s Xolair (omalizumab) has held a monopoly in chronic spontaneous urticaria for some years. Now, though, another agent might end Xolair’s solo reign: Novartis’s own remibrutinib.

Key Takeaways
  • Novartis’s remibrutinib looks set to join Xolair as an approved therapy for chronic spontaneous urticaria
  • But Celldex’s barzolvolimab, at an earlier stage of development, looks as good or better
  • And plenty of other

New data from the twin pivotal trials of remibrutinib, REMIX-1 and -2, suggest that the BTK inhibitor works well whether or not patients have previously taken Xolair. This could, theoretically, allow remibrutinib to become the preferred therapy for urticaria

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

More from R&D

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.